In a nutshell new guidance for Investigational New Drug applications will give the slow and methodical drug development process a much needed shot in the arm, favoring early stage life science companies and academia. The FDA has released new guidelines designed to allow entrance into human Phase 0/I clinical trails with human microdosing based upon [...]

• 49http://clsdf.com/2006/01/phase-0-a-new-era-in-drug-development/Phase+0%3A+A+New+Era+in+Drug+Development2006-01-24+16%3A27%3A00admin

Sirna Therapeutics, Inc. (Nasdaq: RNAI), announced today that the U.S. Patent and Trademark Office has granted Patent No. 6,989,442 for the chemical synthesis and manufacturing of ribonucleic acids. The patent broadly covers a process for the synthesis, deprotection and purification of nucleic acids with one or more ribonucleotides. This process is critical for the efficient [...]

• 48View 2 Comments...http://clsdf.com/2006/01/sirna-granted-patent-for-rnai-production/Sirna+Granted+Patent+for+RNAi+Production2006-01-24+14%3A36%3A00admin